Background: Clozapine impairs gastrointestinal motility owing to its anticholinergic and antiserotonergic properties. This commonly leads to constipation and potentially to more severe complications such as bowel obstruction and ischemia. The aim of this study was to determine whether genetic variations in the genes encoding muscarinic and serotonergic receptors (CHRM2, CHRM3, HTR2, HTR3, HTR4, and HTR7) explain the variations in incidence of constipation and anticholinergic symptoms during clozapine treatment. Genes associated with opiate-induced constipation were also included in this analysis (TPH1, OPRM1, ABCB1, and COMT).
C onstipation is a common adverse effect of clozapine that is reported to occur in 14% to 60% of patients receiving treatment with this drug, 1,2 often leading to increased use of laxative medication. 3 The impairment of gastrointestinal motility associated with clozapine can also result in severe complications such as dysphagia, ileus, intestinal obstruction, bowel ischemia, and megacolon. Among clinicians, these risks seem to be less well known than clozapineinduced agranulocytosis, despite clozapine-induced gastrointestinal hypomotility and agranulocytosis having similar prevalence rates (4.0%-8.0% vs 3.8%-8.0%). Furthermore, clozapineinduced gastrointestinal hypomotility is associated with a greater risk of mortality, and careful monitoring of patients receiving clozapine for symptoms of gastrointestinal hypomotility is recommended. 4, 5 Clozapine-induced constipation seems to be associated with the anticholinergic and antiserotonergic properties of this agent. 5, 6 In the absence of clozapine, acetylcholine stimulates muscarinic receptors in both smooth muscle cells and the interstitial cells of Cajal of the gastrointestinal tract, the latter of which function as the pacemaker cells of the gastrointestinal tract. 7 Muscarinic receptors (of the M 2 and M 3 subtypes) are expressed in interstitial cells of Cajal and smooth muscle cells of the gastrointestinal tract. 8 However, other anticholinergic agents with an efficacy similar to that of clozapine have much lower risks of gastrointestinal hypomotility. For example, the risk of constipation associated with use of clozapine is 3 times greater than that associated with chlorpromazine. 9 Treatment with clozapine is also associated with a higher risk of ileus than that of other antipsychotics, as demonstrated by data from a large European study. 10 This increase in risk is proposed to be caused by the antiserotonergic effects of clozapine. 5 Clozapine is an antagonist of several 5-hydroxytryptamine receptors (5-HT 2 , 5-HT 3 , 5-HT 6 , and 5-HT 7 ). 11 Serotonin also has a complex and crucial but still controversial role in gut function. Data from many studies have suggested that 5-HT receptors, especially 5-HT 3 and 5-HT 4 , have an important role in the regulation of gut motility.
5,12 5-HT 2 receptors have been suggested to modulate visceral sensation, and 5-HT 7 receptors might be involved in mediating relaxation of gastrointestinal smooth muscle. Furthermore, inhibition of 5-HT 3 receptors has been reported to reduce the rate of colon transit, inhibit gastrocolic reflexes, increase the level of colonic compliance, and possibly reduce intestinal sensitivity to distension. 5 The aim of this study was to determine the influence of genetic variations in different subtypes of muscarinic and serotonergic receptors and whether such variations can explain the variable incidence of constipation or anticholinergic symptoms during clozapine treatment. Interactions between such variations and the risk of constipation or anticholinergic symptoms caused by antipsychotic medications have not been studied previously. All muscarinic and serotonergic subtypes that have been previously suggested to have a role in regulating gut motility were included in this study. Single-nucleotide polymorphisms (SNPs) in the genes encoding the M 2 and M 3 muscarinic receptors (CHRM2, CHRM3) and the 5-HT 2 , 5-HT 3 , 5-HT 4 , and 5-HT 7 receptors (HTR2, HTR3, HTR4, and HTR7) were extracted. Additional analyses were performed, including SNPs in TPH1, OPRM1, ABCB1, CHRM3, and COMT, which have all previously been suggested to contribute to the variability in incidence of constipation among patients with cancer receiving treatment with opioids.
13 TPH1 encodes tryptophan 5-hydroxylase 1, which catalyzes the first and rate-limiting step in the biosynthesis of serotonin. 14 TPH1 transcript levels are increased in patients with chronic constipation.
15 OPRM1 encodes the mu-type opioid receptor. ABCB1 encodes multidrug resistance protein 1, a protein that transports various molecules across extracellular and intracellular membranes. Furthermore, ABCB1 is widely expressed in various tissues, including the bowel, blood-brain barrier, liver, and kidneys. 16 COMT encodes catechol O-methyltransferase, an enzyme that catalyzes the degradation of catecholamines such as dopamine, epinephrine, and norepinephrine. 14 
MATERIALS AND METHODS

Patients
The sample was screened from 256 patients, of which 19 declined to participate in this study. Samples were collected from 3 hospital districts in western Finland (Satakunta, Pirkanmaa, and Seinäjoki). Inclusion criteria included a current F2-group diagnosis, according to the International Classification of Diseases, 10th Revision, and a stabilized clozapine treatment. Patients with organic brain diseases were excluded from the analysis. The study population comprised 237 patients receiving clozapine (136 men and 101 women, with a mean age 42.5 ± 11.0 years) who were diagnosed with either schizophrenia (n = 223 [94.1%]), schizoaffective disorder, or delusional disorder. The mean elapsed time from first hospitalization owing to a psychotic episode was 17.3 years (±10.0 years). All patients were adults (≥18 years of age), white, and of Finnish origin. Blood samples were obtained from 190 patients, of which 176 genotyped patients were eligible to remain in the study after quality controls. Patients gave written, informed consent prior to participation. The study was approved by the Ethics Committee of Satakunta Hospital District on April 23, 2008 , and was conducted in accordance with the tenets of the Declaration of Helsinki. More detailed information on the data collection process and the clinical and demographic characteristics of the study population is provided in our previous studies. 17, 18 Of the 176 patients whose samples were genotyped, 57 (32.4%) were receiving a combination of at least 2 antipsychotics, including clozapine, and 119 patients (67.6%) were receiving clozapine monotherapy. All doses of antipsychotic medication were converted to chlorpromazine equivalents. 19 The mean daily dose of clozapine received was 403 (SD, 152)mg or 806 (SD, 304) mg expressed as a chlorpromazine equivalent dose. The mean total antipsychotic dose received was 912 (SD, 304) mg as a chlorpromazine equivalent dose. More than half of all patients had received clozapine treatment for more than 5 years and none for less than 3 months at the time of study enrollment. The demographics of the genotyped patients are presented in Table 1 . Eleven patients were also receiving anticholinergic medications, of which 5 were for the control of extrapyramidal symptoms (biperiden or similar), and 6 were for bladder functional disorders (oxybutynin or trospium chloride).
Patients completed the Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS), 20 a self-assessment questionnaire that consists of a list of 51 symptoms. Patients were asked to rate the severity of each listed adverse effect on a scale from 0 to 4 (0 = not at all, 1 = very little, 2 = a little, 3 = quite a lot, and 4 = very much). Question 10 "constipation" was used as a dichotomized variable with 2 groups: those with no constipation at all (LUNSERS score 0, n = 49) versus those who reported very little to very much constipation (LUNSERS score 1-4, n = 127). A more-specific dichotomized variable was also used as a response variable, which included groups of patients who reported having quite a lot to very much constipation (LUNSERS score 3-4) or were using laxative medications (n = 95), versus those who reported having no constipation at all to a little constipation and were not receiving laxative medications (n = 81). To study patients' anticholinergic symptoms, a factor was formed by summing the severity of the following 5 items from LUNSERS: "dry mouth", "constipation", "palpitations", "difficulty of passing water," and "blurred vision."
DNA Extraction and Genotyping
Genomic DNA was extracted from peripheral blood leukocytes using a QIAamp DNA Blood Midikit and an automated biorobot M48 extraction (Qiagen, Hilden, Germany). Samples were genotyped using an Illumina Infinium HumanCoreExome-12 DNA Analysis Beadchip, version 1.0., according to the manufacturer's instructions at Helmholtz Zentrum, München, Germany. The following quality control filters were applied: GenCall score <0.15, GenTrain score less than 0.20, sample and an SNP call rate less than 0.95, Hardy-Weinberg equation P value less than 10−6, excess heterozygosity, cryptic relatedness (pi-hat >0.2), gender check, and multidimensional scaling. After quality control, 176 samples and 531,983 SNPs were available, of which 192 SNPs were in the genes of interest (CHRM2, CHRM3, HTR2, HTR3, HTR4, HTR7, TPH1, OPRM1, ABCB1, and COMT). Singlenucleotide polymorphisms with a minor allele frequency of less than 0.01 were excluded from the study.
Statistical Methods
Values for comparisons between each group are presented as mean ± SD of the mean, unless otherwise stated. Pearson correlations, χ 2 tests, and t tests were used in exploratory analyses of the relationships between constipation, use of laxatives and anticholinergic factor, and potential explanatory variables such as use of clozapine dose, clozapine and its metabolite norclozapine (N-desmethylclozapine) concentrations, body mass index (BMI), smoking status, age, and use of benzodiazepines or selective serotonin reuptake inhibitors (SSRIs). Reliability analysis for anticholinergic factor was performed using a principal components analysis for ordinal data, using a 1-component solution in which all 5 items were loaded (>0.5). The Cronbach α value was 0.60. Generalized linear univariate models (GLMs) were used to analyze the explanatory factors: SNPs encoded separately with additive, dominant, and recessive coding and covariates for response variables. The response variables analyzed with GLM were dichotomized constipation (binominal distribution), dichotomized constipation taking laxative use into account (binominal distribution), and the anticholinergic factor (Gaussian distribution). Covariates in the models were chosen primarily according to literature and secondarily according to the results of exploratory bivariate analyses. Finally, the best fitting model was used. In the GLM analysis, the SNPs were analyzed by entering them into the model one at a time. To adjust significance levels for multiple testing, the false discovery rate (FDR) was used. This accounts for the number of SNPs and different modes of inheritance in the GLM. Single-nucleotide polymorphisms were coded with additive, dominant, and recessive models. Details of the coding are described in our previous study. 18 The statistical significance level was set at P < 0.05.
Statistical analyses were performed using R statistical analysis software (version 3. 
Genetic Risk Score
Genetic-risk scores (GRSs) were calculated for each patient as a weighted sum of the risk alleles in relation to the studied phenotype. Single-nucleotide polymorphisms that had an unadjusted level of statistical significance (P < 0.05) in the GLM models were selected for further analysis. These SNPs were inserted into the same model with the other coefficients, and a stepwise analysis was performed using Akaike information criteria (AIC). 21 Akaike information criteria are a method of model-based genetic mapping. 22 Data obtained using AIC are used to identify the influential tag SNPs of the SNPs preselected with GLM by also taking into account the extent of linkage disequilibrium (LD) between the SNPs. Single-nucleotide polymorphisms that remained significant, as indicated by AIC, were used in the GRS. The model returned by AIC was analyzed with stepwise variance inflation factor to examine collinearity between the SNPs in the GRS. The corresponding β estimate value from the GLM for each SNP was used to adjust the weighting of individual effects. The formed GRS was then used as an explanatory variable in the final GLM, together with other explanatory variables.
Permutation Test
Linear combinations of genetic effects estimated using GLMs might overfit data and cause inflated type I errors. An estimation of the null distribution of the GRS test statistics is required to validate the GRS results. 23 A permutation test was performed, in which the patient identification numbers from the phenotype data were sampled. This resulted in SNP genotypes that were independent of the studied phenotypes. The permutation was conducted 999 times using the same statistical methods as described previously but with sampled data. P values were collected for GRSs from each model in each sampled data set. The result was considered statistically significant if the P value derived from the actual data analysis was less than 5% of the P values derived from the permutated data.
RESULTS
In exploratory analyses, patients in the group who had more severe constipation or used laxatives were significantly older compared with those who had less severe constipation and required no laxatives (41.34 ± 10.6 vs 44.52 ± 11.6 years of age, t test P = 0.035). No statistically significant associations were observed using analyses of the correlations between dichotomized constipation or anticholinergic factor and age, BMI, smoking status, sex, clozapine dose, or clozapine and norclozapine concentrations. Use of laxatives was associated with BMI (30.4 ± 6.1 vs 28.2 ± 6.3 kg/m 2 , t test P = 0.032), with patients with a lower BMI more likely to be using laxatives. Use of laxatives was also associated with use of benzodiazepines (χ 2 test, P = 0.020), with patients with benzodiazepine medication also more likely to be using laxatives. Anticholinergic factor was also associated with use of benzodiazepines (4.45 ± 3.40 vs 5.38 ± 3.36, t test P = 0.042) and with use of SSRIs (4.59 ± 3.49 vs 5.70 ± 3.13, t test P = 0.015). No correlation between anticholinergic medication use and anticholinergic factor was observed (r = 0.063). Dichotomized constipation was not associated with use of benzodiazepines or SSRIs.
In the GLM analyses, with constipation or use of laxative as the dependent variable, SNPs in CHRM2, CHRM3, HTR2, HTR3, HTR4, and HTR7 with or without the inclusion of additional SNPs in TPH1, OPRM1, ABCB1, and COMT, no statistically significant associations were observed level in any model with varying combinations of additional explaining variables (age, BMI, sex, and use of benzodiazepines or SSRIs). With anticholinergic factor as the dependent variable and BMI and SNPs as the explaining variables, following analysis of SNPs in CHRM2, CHRM3, HTR2, HTR3, HTR4, and HTR7, only rs685548 remained statistically significant after FDR adjustment (dominant coding P = 0.038, additive coding P = 0.044). However, this association became statistically insignificant following FDR adjustment when SNPs associated with opiate-induced constipation were added to this analysis (dominant coding P = 0.060, additive coding P = 0.071).
In the GRS analysis, no significant associations between GRS and constipation or use of laxatives were observed. When only SNPs in CHRM2, CHRM3, HTR2, HTR3, HTR4, and HTR7 were analyzed, associations between the formed GRS and the anticholinergic factor remained statistically insignificant after permutation. When SNPs in genes associated with opiate-induced constipation (ABCB1, OPRM1, TPH1, and COMT) were added to the analysis, a score of 19 SNPs in CHRM2, CHRM3, HTR3C, HTR7, ABCB1, OPRM1, and TPH1 (Table 2 ) was found to be associated with anticholinergic factor in a GLM model with BMI and GRS as explaining variables (P = 0.017). Generalized 0.43 14th of 1000 permutations (P = 0.014) linear univariate model analysis performed only on SNPs associated with opiate-induced constipation and a single SNP in CHRM3 that was associated with anticholinergic factor resulted in a score of 7 SNPs (P = 0.0023, Table 2 ). In both models, no significant collinearity was observed between the SNPs or other predictor variables (variance inflation factor <10).
DISCUSSION
To the best of our knowledge, no previous study has examined the association between clozapine-induced gastric hypomotility or anticholinergic symptoms related to antipsychotic medication and genetic polymorphisms. The main findings of this study are the 2 GRS (Table 2 ) and 1 single SNP in CHRM3 (rs685548) that are associated with anticholinergic symptoms in patients with schizophrenia who are receiving clozapine. This effect is a result of SNPs in various genes, including genes linked with cholinergic (CHRM2 and CHRM3) and serotonergic neurotransmission (HTR3C, HTR7, and TPH1), but also with genes associated with opiate-induced constipation (ABCB1 and OPRM1). This finding might reflect individual genetic variations in response to clozapine or in the functionality of the autonomic nervous system. No statistically significant associations between SNPs in serotonergic or muscarinic receptors or SNPs in genes related to opiate-induced constipation and constipation or laxative use were observed in this study.
The model with the 19-SNP score, BMI, and clozapine monotherapy explained 43% of the variability in anticholinergic symptoms in clozapine-treated patients. The effect was confirmed using a permutation test (P = 0.014), but the high adjusted R 2 value and very low P value in the GLM (<2 Â 10 −16 ) might contain a type I error owing to overfitting in the GRS analysis. The rs685548 SNP located in CHRM3 is an intron variant with a minor allele frequency of 0.36, with no other SNPs with a level of LD of greater than 0.8 r 2 present in this cohort (Table 3) . No significant associations between any phenotype and CHRM3 rs685548 have been reported previously. Furthermore, no items were found in the PubMed database describing any of the SNPs included in the GRSs or SNPs with a level of LD greater than 0.8 r 2 . Single-nucleotide polymorphisms in ABCB1 have been widely investigated. Single-nucleotide polymorphisms in this gene have been studied in relation to patient's responses to clozapine and plasma clozapine levels 24, 25 but not in relation to anticholinergic symptoms. The current study cannot propose a single mechanism explaining the increased risk of anticholinergic symptoms during clozapine treatment, but rather suggests that the genetic effect is cumulative, owing to alterations in muscarinic and serotonergic receptor function (in CHRM2, CHRM3, HTR3C, and HTR7), the serotonin-related enzyme TPH1, and in ABCB1 and OPRM1 function. rs1045642 in ABCB1, which was also included in the GRS, might affect the absorption of clozapine from the gut, as previously reported 24 ; however, in this study, no significant 
<5000 base pairs before gene reading region, no annotation association between serum clozapine and norclozapine concentration and anticholinergic symptoms was observed. The variability in anticholinergic symptoms might also be related to the functions of ABCB1 in other tissues. ABCB1 also has an important functional role in maintaining the blood-brain barrier and blood-cerebral spinal fluid barrier. 16 As Palmer et al 5 state clozapine-induced gastric hypomotility is underrecognized and potentially life-threatening adverse effect of clozapine treatment. Objective evidence of gastrointestinal hypomotility in clozapine-treated patients has been shown by using a colonic transit test. 26 Recent study reported that median colonic transit times are more than 4 times longer than those on other antipsychotics or healthy controls, and four fifths of patients using clozapine had colonic hypomotility. 27 Furthermore, older age, female sex, and treatment with clozapine, tricyclic antidepressants, anticholinergics, and opioids are reported to be associated with an increased risk of ileus. 28 Patients with a greater incidence of anticholinergic symptoms could have an elevated risk of gastric hypomotility and/or bowel complications such as ileus. Thus, the GRSs reported in this study could also be used as markers for the risk of these symptoms. The genes investigated in this study were originally selected based on the hypothesized pharmacological effects of clozapine on the muscarinic and serotonergic receptors that regulate gut motility.
Many confounding factors could not be taken into account by this study, such as variations in diet or amount of exercise, although these can both be expected to influence BMI. In this study cohort, age and sex were both correlated with BMI, which highlights the importance of including BMI in the models used. A total of 192 SNPs were selected for analysis. The ability to detect small or moderate effects associated with these SNPs is limited by the relatively small sample size of the study cohort; however, the well-defined hypothesis and focus only on specific genes reduce the need for a larger sample. A similar statistical approach was used in 3 of our earlier reports, which included the same patient sample. 18, 29, 30 Limitations of this study include the reliance upon self-assessment of the severity of constipation and anticholinergic symptoms by each patient using the LUNSERS questionnaire. No information on patients' bowel movement frequencies or stool consistencies, with the help of stool charts, for example, was available. LUNSERS is, nevertheless, a reliable and validated method of measuring the adverse effects of antipsychotic treatments. 31 Another limitation is that anticholinergic factor, as used to examine the severity of anticholinergic symptoms, is a sum variable with only a moderate level of internal consistency (Cronbach α = 0.6). However, the symptoms included in the anticholinergic factor (dry mouth, constipation, palpitations, difficulty of passing water, and blurred vision) are all commonly recognized anticholinergic symptoms.
32
In conclusion, this study suggests that the risk of anticholinergic symptoms during clozapine treatment is associated with a GRS consisting of SNPs in CHRM2, CHRM3, HTR3C, HTR7, TPH1, ABCB1, and OPRM1 genes, in addition to rs685548 in CHRM3. No significant associations between the genes studied in this analysis and constipation or laxative use were found.
